Page last updated: 2024-11-12

lb-100

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

LB100: a serine-threonine protein phosphatase 2A (PP2A) inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID45101433
CHEMBL ID4297300
SCHEMBL ID9880148
MeSH IDM000604864

Synonyms (18)

Synonym
SCHEMBL9880148
0C1JUU9S0L ,
7-oxabicyclo[2.2.1]heptane-2-carboxylic acid, 3-[(4-methyl-1-piperazinyl)carbonyl]-, (1r,4s)-rel-
3-[(4-methylpiperazin-1-yl)carbonyl]-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
1632032-53-1
lb100
AKOS027338657
lb 100
7-oxabicyclo(2.2.1)heptane-2-carboxylic acid, 3-((4-methyl-1-piperazinyl)carbonyl)-, (1r,4s)-rel-
3-((4-methylpiperazin-1-yl)carbonyl)-7-oxabicyclo(2.2.1)heptane-2-carboxylic acid
unii-0c1juu9s0l
(1r,4s)-3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
gtpl11105
Q27895894
DB15412
CHEMBL4297300
(1r,4s)-lb-100
DTXSID201132163

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Here, we report that a PP2A inhibitor, LB-100, when combined with anti-PD-1 (aPD-1) blockade can synergistically elicit a durable immune-mediated antitumor response in a murine CT26 colon cancer model."( Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.
Gilbert, MR; Heiss, JD; Ho, WS; Kovach, JS; Lu, R; Maggio, D; Marincola, FM; Song, Q; Wang, H; Zhang, Q; Zhuang, Z, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's16 (57.14)24.3611
2020's12 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]